EvolveImmune Therapeutics

A Novel Biotherapeutic that Prevents and Rejuvenates CD8 T Cell Exhaustion

EvolveImmune Therapeutics is developing therapeutics to block or upregulate immune system targets. Co-founders included Sidi Chen and Charlie Fuchs of Yale University and CEO Stephen Block. Elm Street Ventures invested in the original Series A preferred stock financing alongside Pfizer Ventures, Takeda Ventures, and several other investors and in the Series A extension led by Bristol Myers Squibb.